弥漫性大B细胞淋巴瘤（DLBCL）是一种异质性疾病，其临床预后各不相同。我们对其分子组成的理解不断提高风险分层，并且基于人工智能和ctDNA的分析有潜力提升风险评估和疾病监测。R-CHOP和Pola-R-CHP在一线治疗中被使用；嵌合抗原受体治疗（CART）现已成为大多数原发性难治性疾病的新标准护理；CART和自体干细胞移植都在复发和难治性环境中被应用。在本综述中，我们总结了DLBCL的分类和管理，重点介绍了该领域的最新进展。© 2023 Wiley Periodicals LLC.

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with varying clinical outcomes. Our understanding of its molecular makeup continues to improve risk stratification, and artificial-intelligence and ctDNA-based analyses have the potential to enhance risk assessment and disease monitoring. R-CHOP and Pola-R-CHP are used in the frontline setting; chimeric antigen receptor therapy (CART) is now the new standard-of-care for most with primary refractory disease; both CART and autologous stem cell transplantation are utilized in the relapsed and refractory setting. In this review, we summarize the classification and management of DLBCL with an emphasis on recent advances in the field.© 2023 Wiley Periodicals LLC.